+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
PANACEABIO

Panacea Biotec Share Price

₹359.35 +6.65 (1.89%)
44.46% Fall from 52W High

18 Nov, 2026 3:18 PM (IST)

Panacea Biotec live price: ₹359.35. It opened at ₹360 vs previous close ₹353; intraday high/low: ₹362/₹344. The 50 & 200 DMA stand at ₹360.90/₹394.40.

Panacea Biotec Performance

  • Today's Low
  • ₹344
  • Today's High
  • ₹362
  • 52 Week Low
  • ₹292
  • 52 Week High
  • ₹647
  • Open Price₹360
  • Previous Close₹353
  • Volume121,373
  • 50 DMA₹360.90
  • 100 DMA₹382.30
  • 200 DMA₹394.40

Panacea Biotec Chart

Investment Returns

  • Over 1 Month -0.1%
  • Over 3 Month -13.02%
  • Over 6 Month -7.01%
  • Over 1 Year -7.85%

Smart Investing Starts Here Start SIP with Panacea Biotec for Steady Growth!

Invest Now

Panacea Biotec Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 119.6
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 2,201
  • P/B Ratio
  • 2.6
  • Average True Range
  • 15.8
  • EPS
  • 3
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.6
  • RSI
  • 51.75
  • MFI
  • 78.99

Latest Stock News Updates

Q2FY27 Quarterly Result Announced for Panacea Biotec Ltd.

<h3><span style="font-size:16px;"><strong>Biotechnology company Panacea Biotec announced Q2FY27 results</strong></span></h3> <p><strong>Consolidated Financial Highlights:</strong><!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--></p> <ul data-complete="true" data-hveid="CAAIDRAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="aKIYbb_1p"> <li data-complete="true" data-hveid="CAAIDRAC" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_1s"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_1u">Revenue from operations:<!--TgQPHd|||[]--></strong> In Q2FY27, consolidated revenue from operations stood at Rs 18,967 lakh, declining by 4.96% QoQ from Rs 19,957 lakh in Q1FY27 and increasing by 34.39% YoY from Rs 14,113 lakh in Q2FY26. For H1FY27, consolidated revenue from operations grew by 26.45% YoY to Rs 38,924 lakh compared to Rs 30,783 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDRAF" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_21"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_23">Total income:<!--TgQPHd|||[]--></strong> In Q2FY27, consolidated total income stood at Rs 19,627 lakh, registering a decline of 3.70% QoQ from Rs 20,381 lakh in Q1FY27 and a growth of 33.04% YoY from Rs 14,753 lakh in Q2FY26. For H1FY27, consolidated total income rose by 25.06% YoY to Rs 40,008 lakh from Rs 31,990 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDRAI" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_2a"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_2c">Profit before tax (PBT):<!--TgQPHd|||[]--></strong> In Q2FY27, consolidated PBT surged by 375.91% QoQ to Rs 1,699 lakh from Rs 357 lakh in Q1FY27, turning profitable YoY against a loss before tax of Rs 1,917 lakh in Q2FY26. For H1FY27, consolidated PBT turned positive at Rs 2,056 lakh compared to a loss before tax of Rs 1,261 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDRAL" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_2j"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_2l">Profit after tax (PAT):<!--TgQPHd|||[]--></strong> In Q2FY27, consolidated PAT jumped by 441.36% QoQ to Rs 1,191 lakh from Rs 220 lakh in Q1FY27, swinging to a profit YoY against a net loss of Rs 1,401 lakh in Q2FY26. For H1FY27, consolidated PAT stood at Rs 1,411 lakh compared to a net loss of Rs 1,005 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDRAO" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_2s"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_2u">Earnings per share (EPS):<!--TgQPHd|||[]--></strong> In Q2FY27, consolidated basic and diluted EPS rose by 400.00% QoQ to Rs 1.90 from Rs 0.38 in Q1FY27, improving YoY from a loss per share of Rs 2.27 in Q2FY26. For H1FY27, consolidated basic and diluted EPS stood at Rs 2.27 compared to a loss per share of Rs 1.62 in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <!--TgQPHd|||[]--> </ul> <p><!--TgQPHd|||[]--></p> <p><strong>Standalone Financial Highlights:</strong><!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--></p> <ul data-complete="true" data-hveid="CAAIDxAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="aKIYbb_3a"> <li data-complete="true" data-hveid="CAAIDxAC" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_3d"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_3f">Revenue from operations:<!--TgQPHd|||[]--></strong> In Q2FY27, standalone revenue from operations stood at Rs 12,669 lakh, decreasing by 5.95% QoQ from Rs 13,471 lakh in Q1FY27 and increasing by 39.51% YoY from Rs 9,081 lakh in Q2FY26. For H1FY27, standalone revenue from operations increased by 28.73% YoY to Rs 26,140 lakh from Rs 20,306 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDxAD" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_3h"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_3j">Total income:<!--TgQPHd|||[]--></strong> In Q2FY27, standalone total income stood at Rs 13,310 lakh, declining by 5.45% QoQ from Rs 14,077 lakh in Q1FY27 and rising by 40.97% YoY from Rs 9,442 lakh in Q2FY26. For H1FY27, standalone total income grew by 29.42% YoY to Rs 27,387 lakh from Rs 21,162 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDxAE" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_3l"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_3n">Profit before tax (PBT):<!--TgQPHd|||[]--></strong> In Q2FY27, standalone PBT rose by 604.00% QoQ to Rs 1,408 lakh from Rs 200 lakh in Q1FY27, turning profitable YoY against a loss before tax of Rs 2,093 lakh in Q2FY26. For H1FY27, standalone PBT turned positive at Rs 1,608 lakh compared to a loss before tax of Rs 2,977 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDxAF" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_3p"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_3r">Profit after tax (PAT):<!--TgQPHd|||[]--></strong> In Q2FY27, standalone PAT surged by 673.38% QoQ to Rs 1,075 lakh from Rs 139 lakh in Q1FY27, swinging to a profit YoY from a net loss of Rs 1,564 lakh in Q2FY26. For H1FY27, standalone PAT reached Rs 1,214 lakh compared to a net loss of Rs 2,234 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDxAG" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_3t"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_3v">Earnings per share (EPS):<!--TgQPHd|||[]--></strong> In Q2FY27, standalone basic and diluted EPS rose by 665.22% QoQ to Rs 1.76 from Rs 0.23 in Q1FY27, improving YoY from a loss per share of Rs 2.55 in Q2FY26. For H1FY27, standalone basic and diluted EPS stood at Rs 1.98 compared to a loss per share of Rs 3.65 in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <!--TgQPHd|||[]--> </ul> <p><!--TgQPHd|||[]--></p> <p><strong>Business & Segment-Wise Highlights:</strong><!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--></p> <ul data-complete="true" data-hveid="CAAIERAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="aKIYbb_47"> <li data-complete="true" data-hveid="CAAIERAC" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_4a"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_4c">Vaccines segment:<!--TgQPHd|||[]--></strong> In Q2FY27, segment revenue stood at Rs 12,422 lakh, down 7.76% QoQ from Rs 13,467 lakh in Q1FY27 and up 36.79% YoY from Rs 9,081 lakh in Q2FY26, while H1FY27 segment revenue grew by 27.49% YoY to Rs 25,889 lakh from Rs 20,306 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIERAD" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_4e"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_4g">Formulations segment:<!--TgQPHd|||[]--></strong> In Q2FY27, segment revenue increased by 0.85% QoQ to Rs 6,545 lakh from Rs 6,490 lakh in Q1FY27 and grew by 30.07% YoY from Rs 5,032 lakh in Q2FY26, while H1FY27 segment revenue rose by 24.42% YoY to Rs 13,035 lakh from Rs 10,477 lakh in H1FY26.</li> </ul> <p><a class="lb" href="/get-document/post/pdf/5953382/" target="_blank">Result PDF</a></p>

Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Please find attached newspaper copies of the extract of statement of Unaudited Financial Results for the quarter and half year ended September 30, 2026.

Panacea Biotec Ltd - 531349 - Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half-Year Ended September 30, 2026

Please find attached Unaudited Financial Results for quarter and half year ended September 30, 2026

Panacea Biotec Financials

Panacea Biotec Technicals

EMA & SMA

Current Price
₹359.35
+ 6.65 (1.89%)
pointer
  • Bearish Moving Average 6
  • Bullish Moving Average 10
  • 20 Day
  • ₹347.90
  • 50 Day
  • ₹360.90
  • 100 Day
  • ₹382.30
  • 200 Day
  • ₹394.40

Resistance and Support

355.32 Pivot Speed
  • R3 377.60
  • R2 369.30
  • R1 361.00
  • S1 344.40
  • S2 336.10
  • S3 327.80

Panacea Biotec Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-11-14 Quarterly Results
2026-08-13 Quarterly Results
2026-05-30 Audited Results & Dividend
2026-05-29 Audited Results & Dividend
2026-02-11 Quarterly Results
Date Purpose Remarks
2003-02-11 Split Face value changed from Rs. 10/- to Rs. 1/-

Panacea Biotec Shareholding Pattern

72.48%
22.31%
2.75%
2.47%

About Panacea Biotec

Panacea Biotec engaged in the business of research, development, manufacture and marketing of vaccines in India and international markets. View More
  • NSE Symbol
  • PANACEABIO
  • BSE Symbol
  • 531349
  • ISIN
  • INE922B01023

Similar Stocks to Panacea Biotec

Panacea Biotec FAQs

Panacea Biotec share price is ₹359 As on 18 November, 2026 | 15:06

The Market Cap of Panacea Biotec is ₹2201 Cr As on 18 November, 2026 | 15:06

The P/E ratio of Panacea Biotec is 119.6 As on 18 November, 2026 | 15:06

The PB ratio of Panacea Biotec is 2.6 As on 18 November, 2026 | 15:06

The 52 week High & Low of Panacea Biotec is ₹647/₹292.4 respectively As on 18 November, 2026 | 15:06

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23